
Conflixis provides an intelligent automation platform to manage conflicts of interest (COI) in healthcare. They replace outdated manual processes with automated disclosure, review, routing, reporting, and resolution. Their solution aims to make COI disclosures faster, more accurate, and more defensible by leveraging AI and integrating with external data sources like Open Payments. Conflixis helps organizations identify and manage financial relationships, reduce costs associated with conflicted suppliers, and improve transparency and trust within the healthcare ecosystem. Their platform offers features such as smart pre-populated disclosure forms, automated review and scoring, and AI-powered management, leading to significant time savings for compliance teams.

Conflixis provides an intelligent automation platform to manage conflicts of interest (COI) in healthcare. They replace outdated manual processes with automated disclosure, review, routing, reporting, and resolution. Their solution aims to make COI disclosures faster, more accurate, and more defensible by leveraging AI and integrating with external data sources like Open Payments. Conflixis helps organizations identify and manage financial relationships, reduce costs associated with conflicted suppliers, and improve transparency and trust within the healthcare ecosystem. Their platform offers features such as smart pre-populated disclosure forms, automated review and scoring, and AI-powered management, leading to significant time savings for compliance teams.
Sector: Healthcare compliance software (COI management)
Product: AI-powered conflict-of-interest disclosure, review, scoring, and remediation platform
Founded: 2022/2023 (sources report both)
Headquarters: Dallas, Texas (mailing address listed) / New York City reported in some profiles
Seed funding: $4.2M (announced Nov 2024)
Employees: ~10
Conflicts of interest and compliance risk management in healthcare institutions.
Healthcare compliance / SaaS
$4,200,000
Other participants reported: SpringTime Ventures, Mark Ventures, Crētiv Capital
“Backed by early-stage venture firms including Lerer Hippeau and Origin Ventures”